MétaCan
Menu
Back to cohort

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

2023· article· en· W4380685261 on OpenAlexaff
Yu Akahoshi, Nikolaos Spyrou, William J. Hogan, Francis Ayuk, Zachariah DeFilipp, Daniela Weber, Hannah Choe, Elizabeth O. Hexner, Wolf Rösler, Aaron Etra, Karamjeet Sandhu, Gregory A. Yanik, Chantiya Chanswangphuwana, Carrie L. Kitko, Ran Reshef, Sabrina Kraus, Matthias Wölfl, Matthias Eder, Hannah Bertrand, Muna Qayed, Pietro Merli, Stephan A. Grupp, Paibel Aguayo‐Hiraldo, Tal Schechter, Evelyn Ullrich, Janna Baez, Rahnuma Beheshti, Sigrun Gleich, Steven Kowalyk, George Morales, Rachel Young, Deukwoo Kwon, Ryotaro Nakamura, John E. Levine, James L.M. Ferrara, Yi‐Bin Chen

Bibliographic record

VenueBlood Advances · 2023
Typearticle
Languageen
FieldMedicine
TopicHematopoietic Stem Cell Transplantation
Canadian institutionsSickKids FoundationHospital for Sick ChildrenUniversity of Toronto
FundersJapan Society for the Promotion of ScienceNational Institutes of HealthNational Cancer InstituteJosé Carreras Leukämie-Stiftung
KeywordsMedicineCumulative incidenceInternal medicineGraft-versus-host diseaseIncidence (geometry)DiseaseCyclophosphamideBiomarkerHematopoietic stem cell transplantationClinical trialTransplantationImmunologyOncologyChemotherapy

Abstract

fetched live from OpenAlex

Late acute graft-versus-host disease (GVHD) is defined as de novo acute GVHD presenting beyond 100 days after allogeneic hematopoietic cell transplantation (HCT) without manifestations of chronic GVHD. Data are limited regarding its characteristics, clinical course, and risk factors because of underrecognition and changes in classification. We evaluated 3542 consecutive adult recipients of first HCTs at 24 Mount Sinai Acute GVHD International Consortium (MAGIC) centers between January 2014 and August 2021 to better describe the clinical evolution and outcomes of late acute GVHD. The cumulative incidence of classic acute GVHD that required systemic treatment was 35.2%, and an additional 5.7% of patients required treatment for late acute GVHD. At the onset of symptoms, late acute GVHD was more severe than classic acute GVHD based on both clinical and MAGIC algorithm probability biomarker parameters and showed a lower overall response rate on day 28. Both clinical and biomarker grading at the time of treatment stratified the risk of nonrelapse mortality (NRM) in patients with classic and late acute GVHD, respectively, but long-term NRM and overall survival did not differ between patients with classic and late acute GVHD. Advanced age, female-to-male sex mismatch, and the use of reduced intensity conditioning were associated with the development of late acute GVHD, whereas the use of posttransplant cyclophosphamide-based GVHD prevention was protective mainly because of shifts in GVHD timing. Because overall outcomes were comparable, our findings, although not definitive, suggest that similar treatment strategies, including eligibility for clinical trials, based solely on clinical presentation at onset are appropriate.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.362
Teacher spread0.337 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations42
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueBlood AdvancesSame topicHematopoietic Stem Cell TransplantationFrench-language works237,207